Trial
NCT02623439
A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
University of California, San Diego
Collaborators
—
Condition
Hematologic Malignancies
Intervention
Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Why stopped
Toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-10